NRBO
Income statement / Annual
Last year (2023), NeuroBo Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, NeuroBo Pharmaceuticals, Inc.'s net income was -$12.47 M.
See NeuroBo Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$28,000.00
|
$72,000.00
|
$67,000.00
|
$17,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$28,000.00
|
-$72,000.00
|
-$67,000.00
|
-$17,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.16 M
|
$2.78 M
|
$6.55 M
|
$21.87 M
|
$17.48 M
|
$14.31 M
|
$22.69 M
|
$8.74 M
|
$3.99 M
|
$52,000.00
|
| General & Administrative Expenses |
$6.73 M
|
$8.64 M
|
$8.75 M
|
$7.85 M
|
$2.70 M
|
$8.49 M
|
$60,000.00
|
$5.96 M
|
$3.18 M
|
$214,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10.38 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.73 M
|
$8.64 M
|
$8.75 M
|
$7.85 M
|
$2.70 M
|
$8.49 M
|
$10.44 M
|
$5.96 M
|
$3.18 M
|
$214,000.00
|
| Other Expenses |
$0.00
|
-$83,000.00
|
$0.00
|
-$1,000.00
|
$12.15 M
|
-$178,000.00
|
$10.44 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$15.89 M
|
$11.42 M
|
$15.30 M
|
$29.72 M
|
$20.18 M
|
$22.81 M
|
$33.12 M
|
$14.70 M
|
$7.17 M
|
$266,000.00
|
| Cost And Expenses |
$15.89 M
|
$11.42 M
|
$15.30 M
|
$29.72 M
|
$20.18 M
|
$22.81 M
|
$33.12 M
|
$14.70 M
|
$7.17 M
|
$266,000.00
|
| Interest Income |
$461,000.00
|
$2,191.00
|
$14,000.00
|
$39,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$2.19 M
|
$0.00
|
$39,000.00
|
$22,000.00
|
$654,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$7,000.00
|
$28,000.00
|
$72,000.00
|
$67,000.00
|
$17,000.00
|
$6.67 M
|
$60,000.00
|
-$17,000.00
|
$2.01 M
|
-$1,000.00
|
| EBITDA |
-$15.88 M |
-$11.40 M |
-$15.21 M |
-$29.61 M |
-$21.17 M |
-$15.49 M |
-$33.09 M |
-$14.50 M |
-$6.07 M |
-$283,000.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.42 M
|
$5.66 M
|
$14,000.00
|
$38,000.00
|
-$1.14 M
|
-$43,000.00
|
-$291,000.00
|
$110,000.00
|
-$953,000.00
|
-$54,000.00
|
| Income Before Tax |
-$12.47 M
|
-$13.97 M
|
-$15.28 M
|
-$29.68 M
|
-$21.31 M
|
-$23.64 M
|
-$33.42 M
|
-$14.59 M
|
-$9.03 M
|
-$320,000.00
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$7.85 M
|
-$62,000.00
|
-$85,000.00
|
$1.12 M
|
$654,000.00
|
$286,000.00
|
-$136,816.00
|
-$146,000.00
|
$55,000.00
|
| Net Income |
-$12.47 M
|
-$6.12 M
|
-$15.22 M
|
-$29.59 M
|
-$22.43 M
|
-$23.64 M
|
-$33.42 M
|
-$14.59 M
|
-$9.03 M
|
-$320,000.00
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.46 |
-19.01 |
-157.85 |
-437.95 |
-1030.5 |
-166.8 |
-2421.73 |
-1883.28 |
-1277.45 |
-45.27 |
| EPS Diluted |
-2.46 |
-19.01 |
-157.85 |
-437.95 |
-1030.5 |
-166.8 |
-2421.73 |
-1883.28 |
-1277.45 |
-45.27 |
| Weighted Average Shares Out |
$5.07 M
|
$321,703.00
|
$96,432.00
|
$67,572.00
|
$21,767.00
|
$141,710.00
|
$13,798.00
|
$7,745.00
|
$7,068.00
|
$7,068.00
|
| Weighted Average Shares Out Diluted |
$5.07 M
|
$321,703.00
|
$96,432.00
|
$67,572.00
|
$21,767.00
|
$141,710.00
|
$13,798.00
|
$7,745.00
|
$7,068.00
|
$7,068.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
